New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, USA, December…
Read original article on The Medical News →Related news
-
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
United Kingdom
-
What went right this week: the good news that matters
United Kingdom
-
Siemens Healthineers to rebrand in vitro diagnostics business as Olyrian Diagnostics
United Kingdom
-
Income divide in access to psychological care widens, with children hardest hit
United Kingdom
-
%2c_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg)
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
United Kingdom
-
Novel method identifies active tRNAs during cellular protein synthesis
United Kingdom
-
Virtual reality reduces anxiety among children awaiting surgery
United Kingdom
-
New genomic tools improve detection of rare DNA changes
United Kingdom